Cargando…
Incidence of central precocious puberty more than doubled during COVID-19 pandemic: Single-center retrospective review in the United States
BACKGROUND AND AIM OF THE STUDY: The frequency of new visits for precocious puberty increased during the Covid-19 pandemic in the pediatric endocrinology clinic at Rady Children's Hospital in San Diego, CA, US. A few recent studies have shown an increase in the frequency of Central Precocious P...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9748187/ https://www.ncbi.nlm.nih.gov/pubmed/36533230 http://dx.doi.org/10.3389/fped.2022.1007730 |
_version_ | 1784849772360761344 |
---|---|
author | Trujillo, Marcela Vargas Rungvivatjarus, Tiranun Klein, Karen O. |
author_facet | Trujillo, Marcela Vargas Rungvivatjarus, Tiranun Klein, Karen O. |
author_sort | Trujillo, Marcela Vargas |
collection | PubMed |
description | BACKGROUND AND AIM OF THE STUDY: The frequency of new visits for precocious puberty increased during the Covid-19 pandemic in the pediatric endocrinology clinic at Rady Children's Hospital in San Diego, CA, US. A few recent studies have shown an increase in the frequency of Central Precocious Puberty (CPP) in other centers during this pandemic. This study evaluated the change in incidence of new CPP cases requiring treatment with GnRH agonist (GnRHa) at Rady Children's Hospital during the Covid-19 pandemic and compared it to pre-pandemic years. METHODS: Data were reviewed retrospectively to compare the number of visits of children newly diagnosed with CPP treated with GnRHa during the Covid-19 pandemic (5/2020–4/2021) and before the pandemic (5/2018–4/2019). Clinical and bone maturation data were evaluated as well as differences in timing from diagnosis to onset of treatment. The incidence of CPP requiring treatment for 5 years prior to the pandemic was also reviewed to evaluate for trends over time. RESULTS: A total of 92 subjects were included. During pre-Covid year, 28 children (1 boy, 27 girls) were treated with GnRHa for CPP out of 2,340 new endocrinology visits (1.2% of patients seen). During Covid-19 year, 64 children (7 boys, 57 girls) were treated out of 2,261 new visits (2.8%). The incidence of new CPP cases requiring GnRHa during the pandemic more than doubled compared to pre-pandemic. Age at onset of treatment, degree of bone age (BA) advancement, time from diagnosis to onset of treatment, and changes in BMI during the pandemic were not different from pre-pandemic. CONCLUSION: CPP cases requiring GnRHa treatment significantly increased during the first year of the Covid-19 pandemic. This was not related to increased BMI or delay in onset of treatment. Age at diagnosis, degree of bone age advancement, and time from diagnosis to onset of treatment were all similar during the first year of the pandemic compared to the prior year. |
format | Online Article Text |
id | pubmed-9748187 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-97481872022-12-15 Incidence of central precocious puberty more than doubled during COVID-19 pandemic: Single-center retrospective review in the United States Trujillo, Marcela Vargas Rungvivatjarus, Tiranun Klein, Karen O. Front Pediatr Pediatrics BACKGROUND AND AIM OF THE STUDY: The frequency of new visits for precocious puberty increased during the Covid-19 pandemic in the pediatric endocrinology clinic at Rady Children's Hospital in San Diego, CA, US. A few recent studies have shown an increase in the frequency of Central Precocious Puberty (CPP) in other centers during this pandemic. This study evaluated the change in incidence of new CPP cases requiring treatment with GnRH agonist (GnRHa) at Rady Children's Hospital during the Covid-19 pandemic and compared it to pre-pandemic years. METHODS: Data were reviewed retrospectively to compare the number of visits of children newly diagnosed with CPP treated with GnRHa during the Covid-19 pandemic (5/2020–4/2021) and before the pandemic (5/2018–4/2019). Clinical and bone maturation data were evaluated as well as differences in timing from diagnosis to onset of treatment. The incidence of CPP requiring treatment for 5 years prior to the pandemic was also reviewed to evaluate for trends over time. RESULTS: A total of 92 subjects were included. During pre-Covid year, 28 children (1 boy, 27 girls) were treated with GnRHa for CPP out of 2,340 new endocrinology visits (1.2% of patients seen). During Covid-19 year, 64 children (7 boys, 57 girls) were treated out of 2,261 new visits (2.8%). The incidence of new CPP cases requiring GnRHa during the pandemic more than doubled compared to pre-pandemic. Age at onset of treatment, degree of bone age (BA) advancement, time from diagnosis to onset of treatment, and changes in BMI during the pandemic were not different from pre-pandemic. CONCLUSION: CPP cases requiring GnRHa treatment significantly increased during the first year of the Covid-19 pandemic. This was not related to increased BMI or delay in onset of treatment. Age at diagnosis, degree of bone age advancement, and time from diagnosis to onset of treatment were all similar during the first year of the pandemic compared to the prior year. Frontiers Media S.A. 2022-11-30 /pmc/articles/PMC9748187/ /pubmed/36533230 http://dx.doi.org/10.3389/fped.2022.1007730 Text en © 2022 Trujillo, Rungvivatjarus and Klein. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) (https://creativecommons.org/licenses/by/4.0/) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pediatrics Trujillo, Marcela Vargas Rungvivatjarus, Tiranun Klein, Karen O. Incidence of central precocious puberty more than doubled during COVID-19 pandemic: Single-center retrospective review in the United States |
title | Incidence of central precocious puberty more than doubled during COVID-19 pandemic: Single-center retrospective review in the United States |
title_full | Incidence of central precocious puberty more than doubled during COVID-19 pandemic: Single-center retrospective review in the United States |
title_fullStr | Incidence of central precocious puberty more than doubled during COVID-19 pandemic: Single-center retrospective review in the United States |
title_full_unstemmed | Incidence of central precocious puberty more than doubled during COVID-19 pandemic: Single-center retrospective review in the United States |
title_short | Incidence of central precocious puberty more than doubled during COVID-19 pandemic: Single-center retrospective review in the United States |
title_sort | incidence of central precocious puberty more than doubled during covid-19 pandemic: single-center retrospective review in the united states |
topic | Pediatrics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9748187/ https://www.ncbi.nlm.nih.gov/pubmed/36533230 http://dx.doi.org/10.3389/fped.2022.1007730 |
work_keys_str_mv | AT trujillomarcelavargas incidenceofcentralprecociouspubertymorethandoubledduringcovid19pandemicsinglecenterretrospectivereviewintheunitedstates AT rungvivatjarustiranun incidenceofcentralprecociouspubertymorethandoubledduringcovid19pandemicsinglecenterretrospectivereviewintheunitedstates AT kleinkareno incidenceofcentralprecociouspubertymorethandoubledduringcovid19pandemicsinglecenterretrospectivereviewintheunitedstates |